Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet
- PMID: 17876011
- DOI: 10.1200/JCO.2007.12.8900
Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet
Comment on
-
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.J Clin Oncol. 2007 Oct 10;25(29):4557-61. doi: 10.1200/JCO.2007.12.0949. Epub 2007 Sep 17. J Clin Oncol. 2007. PMID: 17876013 Clinical Trial.
-
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.J Clin Oncol. 2007 Oct 10;25(29):4536-41. doi: 10.1200/JCO.2007.11.5154. Epub 2007 Sep 17. J Clin Oncol. 2007. PMID: 17876014 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
